Slithen told reporters: ' This research and development investment is relatively high, at present, many pharmaceutical enterprises in the research and development investment has not been 1% of operat

Medical Network August 16 August 14, Shaoxing Business Bureau of Micro-credit ' Shaoxing business ' released the news that Zhejiang Medicine (600216, SH) in the recent United States hearings to defend, through the public review process, successfully excluding its exports to 34 billion U.S. dollars of goods added 25% tariff list.

At the same time, due to the defense of Zhejiang Medicine, China's fine chemicals, raw materials and pharmaceutical products export enterprises have been exempted from the tariff.

China's sourcing in the United States is irreplaceable In early April this year, the U.S. Trade Representative's office published a list of Chinese goods to be levied on tariffs based on the results of the ' 301 Survey ', and President Trump announced that it would impose tariffs on about 50 billion U.S. dollars of Chinese imports, including fine chemical raw materials and formulations produced by Zhejiang Pharmaceuticals.

Subsequently, Zhejiang Medical organization strength to participate in the United States hearings.

Zhejiang Medicine said that the key to the success of this plea is the Chinese supply source in the U.S. market is irreplaceable. According to the introduction, the current U.S. ' opium crisis ' problem is widely concerned about the infected drug addicts in the United States Standard

Treatment is the use of vancomycin, but the antibiotic resistant bacteria ' super antibiotics ' has been discontinued in the United States, mostly directly imported from China, and Zhejiang Pharmaceutical production of vancomycin accounted for the global production of 50%.

Zhejiang Medicine 2017 Annual report shows that during the reporting period, the company's vancomycin hydrochloride raw materials production and sales are 32 tons, of which most of the direct external sales, part of the production of injection of vancomycin hydrochloride.

In addition, Zhejiang Medicine in the 2017 annual report mentioned the company's development strategy, said that the company's future focus on products from raw materials to the preparation of transfer, sales market from domestic to domestic and international transfer, and will further promote the export of agents and characteristics of the development of raw materials. Economist Song Qinghui that the matter to the domestic Enterprise

Transmit positive signal, to our country enterprise ' go out ' have reference meaning, namely in ' go out ' at the same time to ' stand up ', face unfair treatment should be active to defend or should sue, if swallow insult to admit a plant, will only self-defeating. Beijing Ding-Chen Medical Consulting founder Slithen said: ' China is a major exporter of raw materials, many U.S. drug manufacturers rely on Chinese raw materials, if the Chinese raw materials and other tariffs, the U.S. pharmaceutical companies have also been hit, the defense of the success of the two countries to promote the common demand.

The company says it has not violated intellectual property rights and dumping Public data show that Zhejiang Medicine is a large joint-stock integrated pharmaceutical enterprise formed in 1997. 2017 Annual report shows that the company realized operating income of 5.693 billion yuan a year, an increase of 7.83% from a year earlier; The net profit attributable to shareholders of listed companies was 253 million yuan, which was reduced by 43.76% over a year earlier. This year, a quarterly report showed that the company realized operating income of 1.922 billion yuan in the reporting period, an increase of 61.68% from a year earlier;

The net profit, which is attributable to shareholders of listed companies, is 465 million yuan, up 1838.06% from a year earlier. From the regional distribution, 2017 annual sales of the company to achieve operating income of 3.955 billion yuan, foreign sales to achieve business income of 1.725 billion yuan.

In addition, the annual report also said that the majority of pharmaceutical raw materials for export, and export-oriented, a small number through trading companies, brokers export.

Zhejiang Medicine director told the Daily Economic news reporter, the company most of the export products to win the price advantage, exports to the United States last year accounted for about 30% of overseas sales, this time to obtain U.S. tariff exemption helps to maintain the company's export products international competitiveness. It is noteworthy that the ' 301 investigation ' is aimed at ' infringement of intellectual property ' and ' China's industrial subsidy policy '. Zhejiang Medicine Li Chunbo chairman believes that Zhejiang Medicine vancomycin has not violated intellectual property rights, not low price dumping, do not enjoy government subsidies, products according to the standard C Gmp

Production, with complete ownership of ownership, which is inconsistent with the target of the United States to combat. The announcement shows that Zhejiang Medical research and development investment in the last year is 258 million yuan, accounting for the current operating income of 4.52%.